Search PubMed⌕ Search

Biomedical subjects

B Fournier

Publications and source records attributed to B Fournier.

136 records · Page 8Linked to original sources
PubMedDate not supplied

[Strategy for serum ferritin measurement in 16 to 45 year old women in health screening centers].

Even in industrialized countries, the iron-deficiency anemia is frequent in menstruating women. However, the systematic measurement of serum ferritin is not justified. In this study, a strategy for ferritin measurement has been determined from data of centers for health screening, obtained in 6,098 menstruating women. This strategy is based on biological results (hemoglobin, MCV, RDW, GGT, ALAT) and on responses to the questions about blood donation, birth country and contraceptive habits. The measurement of serum ferritin is realized in 64% menstruating women and 23% have an hypoferritinemia (< 20 mg/l).

Adolescent↗
PubMedDate not supplied

[Iron deficiency in patients over 60 years. Descriptive study in the consultant population of health screening centers].

AIM: The aim of the study was to evaluate the frequency of iron deficiency with serum ferritin in elderly population, and to appreciate the opportunity of early screening according to digestive diseases. SUBJECTS AND METHODS: Data were collected from 3524 men and 3120 women aged 60 to 75 years during a health screening examination. Evaluation of diagnosis and treatment were obtained through questionnaire completed by treating physician. RESULTS: The frequency of hypoferritinemia was about 2.3% in our population (hypoferritinemia was defined by serum ferritin<20 microg/L or between 20-40 microg/L if C reactive protein was > 12 mg/L). Anemia was found in 3.3% of patients. Logistic regression model adjusting for multiple variables was used to examine factors associated with hypoferritinemia. The probability was greater among non-anemic patients with chronic digestive bleeding (odds-ratio: 2.3), or with positive occult blood testing (odds-ratio: 2.3). Information about the medical follow-up was obtained in 81% of patients with hypoferritinemia. A digestive exploration was made in 38 cases. Digestive disease was found among 24.3% patients with hypoferritinemia, and three colorectal cancers were observed. CONCLUSION: The screening of hypoferritinemia in elderly population examined in health screening centres could not be recommended as its frequency was low in this population, despite a strong correlation between hypoferritinemia and digestive diseases.

Aged↗
PubMedDate not supplied

Comparison between ketanserin and LY 53857 on vascular and cardiac 5-HT2 and alpha 1-adrenergic receptors in the pithed rat.

In normotensive pithed rats, both ketanserin and LY 53857 potently antagonized the increase in blood pressure induced by 5-HT in a noncompetitive manner. However, LY 53857 differs from ketanserin in that it shifts the pressor dose-response curve to 5-HT in a parallel way at low doses but in a noncompetitive way at higher doses. Ketanserin and LY 53857 were weak antagonists of the pressor effects of phenylephrine. LY 53857 was more potent and more selective than ketanserin for 5-HT2 vs alpha 1-adrenergic receptors.

Adrenergic alpha-Antagonists↗
PubMedDate not supplied

Participation of sympathetic and vagal tones in the hypotensive and bradycardic effects of some 5-HT1-like receptor agonists in the rat.

In normotensive anaesthetized rats, 8-OH-DPAT, RU 24969 and 5-MeODMT, three 5-HT1-like receptor agonists, decreased blood pressure and heart rate. The decrease in blood pressure was suppressed by pithing or pretreatment with hexamethonium. Bilateral section of the vagus nerves, pretreatment with a beta-adrenoceptor blocking agent or with atropine, combination of bivagotomy plus beta-adrenoceptor blockade strongly reduced the bradycardia. These results are compatible with a centrally-mediated decrease in sympathetic tone and increase in vagal tone, as the cause of the hypotension and bradycardia induced by these 5-HT1-like receptor agonists in normotensive anaesthetized rats.

8-Hydroxy-2-(di-n-propylamino)tetralin↗
PubMedDate not supplied

Cardiovascular properties of a 5-HT1-like receptor agonist, 5-methoxy-3(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (RU 24969) in normotensive anaesthetized rats.

Intravenous administration of the putative 5-HT1-like receptor agonist RU 24969 (10-1000 micrograms/kg) in anaesthetized rats induced a decrease in heart rate and blood pressure. The bradycardia was reduced, but not suppressed, by tertatolol, bilateral vagotomy or the combination of both treatments. The alpha 1-adrenoceptor blocking agent, AR-C 239, decreased the bradycardia induced by high doses of RU 24969. After treatment with hexamethonium, RU 24969 induced an increase in arterial blood pressure. The hypotensive response induced by RU 24969 was not altered by atropine. The hypotensive and bradycardic effects of RU 24969 were antagonized by methysergide (5-HT1-like receptor antagonist) and in part by spiroxatrine (5-HT1A receptor antagonist). Ketanserin (5-HT2 receptor antagonist) potentiated the effects of low doses of RU 24969. The cardiovascular effects of RU 24969 were antagonized neither by MDL 72222 nor by ICS 205-930 (5-HT3 receptor antagonists). The present results suggest that the cardiovascular effects of RU 24969 seem to be due to the stimulation of 5-HT1-like receptors. The participation of both 5-HT1A and 5-HT1B receptors subtypes has been considered. The results suggest a centrally-mediated inhibition of sympathetic tone and increase in vagal tone in the cardiovascular effects of RU 24969.

Adrenergic beta-Antagonists↗
PubMedDate not supplied

[Comparative study of piperoxan and 2-(2-imidazolinyl)-1, 4-benzodioxane (170 150) on pre- and postsynaptic receptors in the rat].

1. 170 150 (imidazolinyl-2)-2-benzodioxane 1-4), as does piperoxan, competitively antagonizes the hypertension induced by clonidine in the pithed rat. Piperoxan appears slightly less potent than 170 150 in this preparation as shown by the comparison of the apparent pA10 values: 5.3 for piperoxan versus 5.4 for 170 150. 2. The two drugs antagonize the reduction of the electrically-induced tachycardia produced by clonidine. 170 150 appears to be 3-fold more potent than piperoxan in this preparation. 3. These results are compatible with a blockade of alpha 2-pre and postsynaptic adrenoceptors of the rat by piperoxan and 170 150 appears to be 3-fold more potent than piperoxan in this preparation. 3. These results are compatible with a blockade of alpha 2-pre and postsynaptic adrenoceptors of the rat by piperoxan and 170 150 and they are in agreement with our previous results which indicate that compound 170 150 shows a preferential affinity for alpha 2-adrenoceptors.

Animals↗
PubMedDate not supplied

[Acute cholecystitis without gallstones following gastrectomy. A report on two cases (author's transl)].

Two recent cases of acute cholecystitis without gallstones following gastrectomy are reported. Details of the cases are described and the rare nature of this postoperative complication emphasized. Clinical diagnosis is difficult and the cause of this complication is usually not ascertained. Cholecystectomy remain the basic treatment, of choice, but cholecystotomy or simple drainage may be the only possible therapy, and should be employed whenever necessary. Postoperative acute cholecystitis is rarely observed, is usually associated with gallstones, and occurs in patients with previously healthy gallbladders in only exceptional cases, usually following digestive tract operations (Thomoret and Bronstein, 9). The initial surgical intervention then involves the stomach, whether it be a gastrectomy or vagotomy (Champeau, Delattre, 2). Two recent cases of post-gastrectomy acute cholecystitis without gallstones led to a review of the published literature to determine the frequency of this complication, and an attempt to define its characteristics.

Acute Disease↗
PubMedDate not supplied

[Criteria for addition of apolipoprotein B measurement during routine health screening examinations: validation in a Stanislas cohort. The Biologist's Group of the Health Examination Center].

The purpose of this study was to determine the criteria in which apolipoproteins AI and B should be performed during periodic health screening examinations. Clinically, the results of apolipoproteins AI and B are most useful when there are minor lipid perturbations (cholesterol and triglycerides), but their routine determination is not justified. Several mathematical models, defined by discriminate factorial analysis, have been studied. The one based uniquely on cholesterol and triglyceride concentrations was the most efficient in identifying patients in whom apolipoprotein B should be determined. In contrast, no model was found for the indication of apolipoprotein AI determination. Data from a population different from that used for the model establishment were used to validate the model. This strategy, determining criteria for additional measurement of apolipoprotein B in a general population, is of clinical interest because it may provide complementary information for subjects with atherogenic risk. Moreover, it is of economical interest because it has the potential of limiting complementary testing and its associated costs.

Adult↗